Target Gene Table ▼
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10017640HBVENSG00000130816.17protein_codingDNMT1YesNo1786I6L9H2
P26358
TVIS10041678HBVENSG00000130816.17protein_codingDNMT1YesNo1786I6L9H2
P26358
TVIS10050115HBVENSG00000130816.17protein_codingDNMT1YesNo1786I6L9H2
P26358
TVIS30012521HIVENSG00000130816.17protein_codingDNMT1YesNo1786I6L9H2
P26358
TVIS30007412HIVENSG00000130816.17protein_codingDNMT1YesNo1786I6L9H2
P26358
TVIS30002955HIVENSG00000130816.17protein_codingDNMT1YesNo1786I6L9H2
P26358
TVIS30015668HIVENSG00000130816.17protein_codingDNMT1YesNo1786I6L9H2
P26358
TVIS30002956HIVENSG00000130816.17protein_codingDNMT1YesNo1786I6L9H2
P26358
TVIS30002957HIVENSG00000130816.17protein_codingDNMT1YesNo1786I6L9H2
P26358
TVIS30012522HIVENSG00000130816.17protein_codingDNMT1YesNo1786I6L9H2
P26358
TCGA Plot Options ▼
Drug Information ▼
GeneDNMT1
DrugBank IDDB01262
Drug NameDecitabine
Target IDBE0000892
UniProt IDP26358
Regulation Typeinhibitor
PubMed IDs11069027; 11259619; 11352938; 11688997; 12907443; 11752352; 20072836; 16015501; 18398832; 18425818; 17023173; 29455551; 17991895
CitationsAndo T, Nishimura M, Oka Y: Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells. Leukemia. 2000 Nov;14(11):1915-20.@@Karpf AR, Moore BC, Ririe TO, Jones DA: Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. Mol Pharmacol. 2001 Apr;59(4):751-7.@@Csankovszki G, Nagy A, Jaenisch R: Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation. J Cell Biol. 2001 May 14;153(4):773-84.@@Takebayashi S, Nakao M, Fujita N, Sado T, Tanaka M, Taguchi H, Okumura K: 5-Aza-2'-deoxycytidine induces histone hyperacetylation of mouse centromeric heterochromatin by a mechanism independent of DNA demethylation. Biochem Biophys Res Commun. 2001 Nov 9;288(4):921-6.@@Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J: Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 2003 Dec 1;102(12):3865-70. Epub 2003 Aug 7.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Recent Results Cancer Res. 2010;184:131-57. doi: 10.1007/978-3-642-01222-8_10.@@Saba HI, Wijermans PW: Decitabine in myelodysplastic syndromes. Semin Hematol. 2005 Jul;42(3 Suppl 2):S23-31.@@Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun;112(11):2341-51. doi: 10.1002/cncr.23463.@@Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008 Jul 1;123(1):8-13. doi: 10.1002/ijc.23607.@@Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4.@@Seelan RS, Mukhopadhyay P, Pisano MM, Greene RM: Effects of 5-Aza-2'-deoxycytidine (decitabine) on gene expression. Drug Metab Rev. 2018 May;50(2):193-207. doi: 10.1080/03602532.2018.1437446. Epub 2018 Feb 18.@@Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD: DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008 Jan;28(2):752-71. Epub 2007 Nov 8.
GroupsApproved; Investigational
Direct ClassificationTriazinones
SMILESNC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1
Pathways
PharmGKBPA164749631
ChEMBLCHEMBL1201129